PaulaRaffinPohlmannMD

PubMed

• Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy.
  Mark Jesus M Magbanua, Ziad Ahmed, Rosalyn W Sayaman, Lamorna Brown Swigart, Gillian L Hirst, Christina Yau, Denise M Wolf, Wen Li, Amy L Delson, Jane Perlmutter, Paul...> ;Clinical Cancer Research. 2024 Mar 12
• Co-Clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts.
  DiPeri, T., Evans, K., Wang, B., Zhao, M., Akcakanat, A., Raso, M., Rizvi, Y., Zheng, X., Korkut, A., Varadarajan, K., Uzunparmak, B., Dumbrava, E., Pant, S., Ajani, J...> ;Cancer Discovery. 2024 Feb 15
• Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial.
  Haiyun Wang, Douglas Yee, David Potter, Patricia Jewett, Christina Yau, Heather Beckwith, Allison Watson, Nicholas O'Grady, Amy Wilson, Susie Brain, Paula Pohlmann, , ...> ;Breast Cancer Research and Treatment. 2024 Apr 1
• 1 citations
  Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
  Gallagher, R., Wulfkuhle, J., Wolf, D., Brown-Swigart, L., Yau, C., O'Grady, N., Basu, A., Lu, R., Campbell, M., Magbanua, M., Coppé, J., , Asare, S., Sit, L., Matthew...> ;Cell Reports. Medicine. 2023 Dec 19
• 5 citations
  Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.
  Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, Jean-Luc Canon, Matthew D Galsky, Erika Hamilton, Hidetoshi Hayashi, Guy Jerusalem, Seung Tae Kim, Keun-Wook Lee, Lion...> ;Journal of Clinical Oncology. 2023 Dec 20
• 2 citations
  A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refract...
  Tina Roy, Elizabeth Barrows, Candace Mainor, Julie Collins, Filipa Lynce, Claudine Isaacs, Paula R Pohlmann> ;Contemporary Clinical Trials Communications. 2023 Jun 1
• Impact of Body Mass Index on Pathological Response after Neoadjuvant Chemotherapy: Results from the I-SPY 2 trial.
  Haiyun Wang, Douglas Yee, David Potter, Patricia Jewett, Christina Yau, Heather Beckwith, Allison Watson, Nicholas O'Grady, Amy Wilson, Susie Brain, Paula Pohlmann, An...> ;Research Square. 2023 May 31
• 3 citations
  Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression.
  Gary Tozbikian, Savitri Krishnamurthy, Marilyn M Bui, Michael Feldman, David G Hicks, Shabnam Jaffer, Thaer Khoury, Shi Wei, Hannah Wen, Paula Pohlmann> ;Archives of Pathology & Laboratory Medicine. 2024 Feb 1
• 3 citations
  Propagated Circulating Tumor Cells Uncover the Potential Role of NFκB, EMT, and TGFβ Signaling Pathways andin Metastasis.
  Xiao, J., Jerry Xiao, Utsav Sharma, Abolfazl Arab, Sohit Miglani, Sonakshi Bhalla, Shravanthy Suguru, Robert Suter, Reetu Mukherji, Marc E Lippman, Paula R Pohlmann, J...> ;Cancers. 2023 Mar 17
• 3 citations
  HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving...
  Paula R Pohlmann, Deena Graham, Tianmin Wu, Yvonne Ottaviano, Mahsa Mohebtash, Shweta Kurian, Donna McNamara, Filipa Lynce, Robert Warren, Asma Dilawari, Suman Rao, Ca...> ;Breast Cancer Research and Treatment. 2022 Dec 1
• 3 citations
  Molecular characterization of ESR1 variants in breast cancer.
  Arielle L Heeke, Andrew Elliott, Rebecca Feldman, Hazel F O'Connor, Paula R Pohlmann, Filipa Lynce, Sandra M Swain, Maria R Nunes, Daniel Magee, Matthew J Oberley, Jef...> ;Breast Cancer Research and Treatment. 2022 Nov 1
• 73 citations
  Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
  Denise M Wolf, Christina Yau, Julia Wulfkuhle, Lamorna Brown-Swigart, Rosa I Gallagher, Pei Rong Evelyn Lee, Zelos Zhu, Mark J Magbanua, Rosalyn Sayaman, Nicholas O'Gr...> ;Cancer Cell. 2022 Jun 13
• 17 citations
  Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux.
  Brandon C Jones, Paula R Pohlmann, Robert Clarke, Surojeet Sengupta> ;Cancer Metastasis Reviews. 2022 Jun 1
• 7 citations
  Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions.
  Giovana R Onzi, Nathalia D'Agustini, Solange C Garcia, Silvia S Guterres, Paula R Pohlmann, Daniela D Rosa, Adriana R Pohlmann> ;Drug Safety. 2022 Jun 1
• 8 citations
  Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TB...
  Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A Yardley, Steven J Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Jiani...> ;NPJ Breast Cancer. 2022 Feb 16
• 12 citations
  Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
  Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kath...> ;NPJ Breast Cancer. 2021 Oct 5
• 18 citations
  Circulating Tumor Cells: Technologies and Their Clinical Potential in Cancer Metastasis.
  Paula R. Pohlmann, Claudine Isaacs, Benjamin A. Weinberg, Aiwu R. He, Richard Schlegel, Seema Agarwal, Xiao, J., Jerry Xiao> ;Biomedicines. 2021 Aug 30
• 7 citations
  Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer.
  Filipa Lynce, Matthew Blackburn, Rebecca Zhuo, Christopher Gallagher, Olwen Hahn, Maysa M. Abu-Khalaf, Mahsa Mohebtash, Tianmin Wu, Paula R. Pohlmann, Asma Dilawari, S...> ;Cancer. 2021 Oct 1
• 14 citations
  Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Tr...
  Kathryn J. Ruddy, Yue Zheng, Nabihah Tayob, Jiani Hu, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese M. Mulvey, Ron Bose,...> ;Breast Cancer Research and Treatment. 2021 Jun 12
• 64 citations
  Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
  Sara M. Tolaney, Nabihah Tayob, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese M. Mulvey, Ron Bose, Jiani Hu, Douglas Wec...> ;Journal of Clinical Oncology. 2021 Jun 2
• 17 citations
  Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compr...
  Katia E. Khoury, Filipa Lynce, Ana Barac, Xue Geng, Chau T. Dang, Anthony F. Yu, Karen L. Smith, Christopher Gallagher, Paula R. Pohlmann, Raquel Nunes, P. Herbolsheim...> ;Breast Cancer Research and Treatment. 2021 Jan 5
• 2 citations
  An evaluation of palbociclib as a breast cancer treatment option: a current update
  Gregory T Gallanis, Ramon I Pericas, Anna T. Riegel, Paula R. Pohlmann> ;Expert Opinion on Pharmacotherapy. 2021 Feb 11
• 11 citations
  Tumor Size as a Surrogate End Point for the Detection of Early Breast Cancer: A 30‐Year (1972–2002), Single‐Center Experience in Southern Brazil
  Carlos Henrique Menke, Paula R. Pohlmann, Ariane Backes, Rodrigo Cericatto, Mônica Oliveira, Ana Cristina da Costa Bittelbrunn, Gilberto Schwartsmann> ;The Breast Journal. 2007 Sep 1
• 10 citations
  Efficient Propagation of Circulating Tumor Cells: A First Step for Probing Tumor Metastasis.
  Joseph R. McGill, Kelly P. Stanton, Joshua D. Kassner, Sujata Choudhury, Richard Schlegel, Zuben E. Sauna, Paula R. Pohlmann, Seema Agarwal, Xiao, J., Jerry Xiao> ;Cancers. 2020 Sep 28
• 9 citations
  Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer.
  Katia E. Khoury, Antoinette R. Tan, Andrew Elliott, Joanne Xiu, Zoran Gatalica, Arielle L Heeke, Claudine Isaacs, Paula R. Pohlmann, Lee S. Schwartzberg, Michael S. Si...> ;Frontiers in Oncology. 2020 Aug 31
• Join now to see all